Electric lamp and discharge devices: consumable electrodes – With economizer
Patent
1995-01-17
1996-12-31
Chang, Ceila
Electric lamp and discharge devices: consumable electrodes
With economizer
514277, 514319, 514327, 514345, 546205, 546217, 546240, 546241, 546285, 546291, 546344, A61K 31445, C07D21122
Patent
active
055894860
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
The invention relates to novel N-hydroxyalkyl substituted 1,2,3,6-tetrahydropyridine and piperidine derivatives, to processes and intermediates for their preparation, to pharmaceutical compostions containing them and to their medical use.
BACKGROUND OF THE INVENTION
International Patent Application PCT/HU90/00076 describes tetrahydropyridine derivatives structurally related to the compounds of the invention which are said to have antiamnesic activity. In contrast to the present compounds, however, said compounds can be considered as .beta.- or .tau.-amino ketone compounds the nitrogen atom of which is closed as a ring member into said substituted tetrahydropyridine ring.
The invention relates to novel, therapeutically active N-hydroxyalkyl-substituted 1,2,3,6-tetrahydropyridine and piperidine derivatives of the formula ##STR2## wherein A is hydrogen or halogen; alkoxy; cyano; phenyl; phenyl monosubstituted by halogen; benzyl; benzyl monosubstituted by halogen; 2-phenylethyl monosubstituted by halogen on the phenyl moiety; or 2-picolyl group; halogen-monosubstituted benzyl; and
Alkyl group as used herein either in itself or as a moiety of another group, is a straight or branched chain saturated hydrocarbon group containing 1-10 carbon atoms such as methyl, ethyl, n- and isopropyl, n-, o-, sec- and tert-butyl groups as well as the various pentyl, hexyl, heptyl, octyl, nonyl and decyl groups. C.sub.1-6 alkyl groups are preferred, C.sub.1-4 alkyl groups are more preferable and methyl group is particularly favorable.
Halogen may mean fluorine, chlorine, bromine or iodine.
The following compounds are particularly preferred: ol, ol, ropanol.
The present invention also relates to a pharmaceutical composition for treating conditions selected from hypoxia and ischaemia comprising an amount of a compound of formula (I) or a pharmaceutically acceptable acid addition salt thereof effective in treating such conditions and a pharmaceutically acceptable carrier.
Furthermore, the present invention also relates to a process and intermediates for the preparation of the compounds of formula (I), as well as acid addition salt thereof.
Additionally, the present invention relates to a process for the preparation of pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable acid addition salt thereof.
The present invention also relates to a method of treatment, which comprises administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically accaptable acid addition salt thereof to a mammal (including man) for strengthening its tolerance against hypoxic and/or ischaemic conditions as well as for treating degenerative and functional disturbances arising from hypoxic and/or ischaemic insults.
Surprisingly, it has been found that the compounds of formula (I) are capable to protect the brain from the cognitive function-injuring effect of various harmful conditions, e.g. hypoxia and/or ischaemia; or they are useful to enhance the tolerance against hypoxic and/or ischaemic conditions, respectively as well as to treat degenerative and functional disturbances arising from hypoxic and ischaemic insults.
The biological effects of compounds according to the invention are hereinafter illustrated by using the following test methods.
Male CFLP mice (from the Hungarian stock LATI) weighing 24-26 g each and spontaneously hypertensive (SH) male rats weighing 160-180 g each, respectively were used in these investigations. The compounds to be tested were orally administered in a volume of 10 ml/kg one hour prior to starting the experiment.
ANTIHYPOXIC EFFECT IN MICE
1. The Cytotoxic Hypoxia Test
After a 1-hour pretreatment, the animals were intravenously injected with 5 mg/kg of potassium cyanide. Survival time was measured as an interval lasting from the administration of potassium cyanide to the last respiratory movement. In the groups consisting of 10 animals each treated with the compounds, the animals having a survival time longer by 30% t
REFERENCES:
patent: 3209006 (1965-09-01), Wragg et al.
patent: 3922266 (1975-11-01), Katsube et al.
patent: 3936468 (1976-02-01), Yamamoto et al.
patent: 4012515 (1977-03-01), Katsube et al.
patent: 4254129 (1981-03-01), Carr et al.
patent: 4254130 (1981-03-01), Carr et al.
patent: 5225416 (1993-06-01), Gizur et al.
Arimura et al. "Butyronaphthones as psycho drugs" CA 74:99715 (1971).
Ibanez-Paniello "Reduction of p,p'-difluoro-benzophenone" CA 80:70478 (1974).
Agai-Csongor Eva
Bod Peter
Bodo Mihaly
Csehi Attila
Csizer Eva
Chang Ceila
Dubno Herbert
Myers Jonathan
Richter Gedeon Vegyeszeti Gyar Rt.
LandOfFree
N-hydroxyalkyl-substituted 1,2,3,6-tetrahydro-pyridine and piper does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-hydroxyalkyl-substituted 1,2,3,6-tetrahydro-pyridine and piper, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-hydroxyalkyl-substituted 1,2,3,6-tetrahydro-pyridine and piper will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1142355